US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Orexigen Therapeutics

0.2229

0.0000

Volume:- -

Turnover:- -

Market Cap:4.21M

PE:-0.02

High:0.2229

Open:0.2229

Low:0.2229

Close:0.2229

52wk High:3.81

52wk Low:0.1708

Shares:18.89M

Float Shares:9.68M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.7006

ROE:--

ROA:--

PB:-0.07

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Orexigen Therapeutics

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.orexigen.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in the United States, Canada, and Mexico. The companys product, Contrave also approved under the brand name of Mysimba in Europe. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OREX/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OREX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OREX\",,,,,undefined,":{"symbol":"OREX","market":"US","secType":"STK","nameCN":"Orexigen Therapeutics","latestPrice":0.2229,"timestamp":1522785600000,"preClose":0.2229,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":9677447,"shares":18887033,"eps":-9.700626,"marketStatus":"Delisted","change":0,"latestTime":"02-10 09:42:35 EST","open":0.2229,"high":0.2229,"low":0.2229,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-9.700626,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1177560000000,"exchange":"NASDAQ","adjPreClose":0.2229,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OREX\",,,,,undefined,":{"symbol":"OREX","floatShares":9677447,"roa":"--","roe":"--","lyrEps":0,"shares":18887033,"dividePrice":0,"high":0.2229,"amplitude":0,"preClose":0.2229,"low":0.2229,"week52Low":0.1708,"pbRate":"-0.07","week52High":3.805,"institutionHeld":0.9018,"latestPrice":0.2229,"eps":-9.700626,"divideRate":0,"volume":0,"delay":0,"ttmEps":-9.700626,"open":0.2229},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OREX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-11-13","symbol":"OREX","fiscalQuarterEnding":"2017/09","expectedEps":-2.13,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1510549200000,"reportTimeType":"post","actualEps":-1.35},{"market":"US","date":"2017-08-08","symbol":"OREX","fiscalQuarterEnding":"2017/06","expectedEps":-2.4,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1502164800000,"reportTimeType":"post","actualEps":-1.82},{"market":"US","date":"2017-05-09","symbol":"OREX","fiscalQuarterEnding":"2017/03","expectedEps":-2.6,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1494302400000,"reportTimeType":"post","actualEps":-4.67},{"market":"US","date":"2017-03-28","symbol":"OREX","fiscalQuarterEnding":"2016/12","expectedEps":-0.54,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1490673600000,"reportTimeType":"pre","actualEps":-2.67},{"market":"US","date":"2016-11-03","symbol":"OREX","fiscalQuarterEnding":"2016/09","expectedEps":-2.13,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1478145600000,"reportTimeType":"post","actualEps":-1.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OREX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OREX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.orexigen.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in the United States, Canada, and Mexico. The companys product, Contrave also approved under the brand name of Mysimba in Europe. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.","exchange":"NASDAQ","name":"Orexigen Therapeutics","nameEN":"Orexigen Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OREX\",market:\"US\",,,undefined,":null}}